The baseline characteristics of CRC cases, CRA cases and non-neoplastic cases are summarized in Table 1. Compared with non-neoplastic cases, a higher prevalence of diabetes mellitus was observed in total (P = 0.016) and male (P = 0.031) CRC cases. Compared with CRA cases and non-neoplastic cases separately, more CRC cases lost weight obviously, both for male and female. CRC cases did not differ significantly from CRA cases and non-neoplastic cases with regard to sex, age, hypertension, coronary heart disease, smoking status, drinking history and family cancer history.
Table 1
baseline characteristics of colorectal cancer cases, colorectal adenoma cases and non-neoplastic cases.
Characteristic | Colorectal cancer cases | Colorectal adenoma cases | Non-neoplastic cases | F(B) or X2 value | P value |
Sex(cases) | | | | 0.143 | 0.931 |
Male | 51(63.8) | 49(61.3) | 51(63.8) | | |
Female | 29(36.3) | 31(38.8) | 29(36.3) | | |
Age (years) | 62.86 ± 9.62 | 61.88 ± 7.66 | 62.03 ± 9.58 | 0.280 | 0.756 |
Male | 62.84 ± 8.19 | 60.59 ± 8.46 | 62.51 ± 8.64 | 1.032 | 0.359 |
Female | 62.90 ± 11.89 | 63.9 ± 5.75 | 61.17 ± 11.16 | 0.566(B) | 0.571 |
Hypertension(cases) | 41(51.3) | 31(38.8) | 29(36.3) | 4.240 | 0.120 |
Male | 26(51.0) | 23(46.9) | 18(35.3) | 2.736 | 0.255 |
Female | 15(51.7) | 8(25.8) | 11(37.9) | 4.265 | 0.119 |
Systolic blood pressure (mmHg) | 133.78 ± 20.13 | 134.09 ± 17.15 | 129.26 ± 14.96 | 1.896(B) | 0.152 |
Male | 135.08 ± 21.02 | 133.37 ± 16.75 | 128.47 ± 13.58 | 1.982(B) | 0.142 |
Female | 131.48 ± 18.59 | 135.23 ± 17.98 | 130.66 ± 17.30 | 0.556 | 0.575 |
Diastolic blood pressure (mmHg) | 80.00(55.0-116.0) | 80.00(65.0-110.0) | 80.00(53.0-110.0) | 2.330 | 0.312 |
Male | 80.00(55.0-116.0) | 80.00(65.0-110.0) | 80.00(60.0-110.0) | 0.920 | 0.631 |
Female | 79.55 ± 12.22 | 82.52 ± 10.75 | 77.93 ± 11.53 | 1.232 | 0.297 |
Coronary heart disease(cases) | 18(22.5) | 8(10.0) | 11(13.8) | 5.049 | 0.080 |
Male | 11(21.6) | 5(10.2) | 7(13.7) | 2.635 | 0.268 |
Female | 7(24.1) | 3(9.7) | 4(13.8) | 2.425 | 0.289 |
Diabetes mellitus(cases)# | 16(20.0) | 7(8.8) | 5(6.3) | 8.329 | 0.016 |
Male# | 11(21.6) | 4(8.2) | 3(5.9) | 6.951 | 0.031 |
Female | 5(17.2) | 3(9.7) | 2(6.9) | 1.623 | 0.444 |
Smoking status(cases) | 36(45.0) | 22(27.5) | 25(31.3) | 6.004 | 0.050 |
Male | 33(64.7) | 22(44.9) | 24(47.1) | 4.784 | 0.091 |
Female | 3(10.3) | 0(0) | 1(3.4) | 4.646 | 0.098 |
Drinking history(cases) | 7(8.8) | 10(12.5) | 14(17.5) | 2.741 | 0.254 |
Male | 7(13.7) | 10(20.4) | 13(25.5) | 2.230 | 0.328 |
Female | 0(0) | 0(0) | 1(3.4) | 1.534 | 0.215 |
Family cancer history (cases) | 19(23.8) | 18(22.5) | 16(20.0) | 0.339 | 0.844 |
Male | 10(19.6) | 6(12.2) | 8(15.7) | 1.016 | 0.602 |
Female | 9(31.0) | 12(38.7) | 8(27.6) | 0.891 | 0.641 |
Weight loss(cases)*# | 34(42.5) | 6(7.5) | 5(6.3) | 44.472 | 0.000 |
Male*# | 21(41.2) | 3(6.1) | 3(5.9) | 28.463 | 0.000 |
Female*# | 13(44.8) | 3(9.7) | 2(6.9) | 16.21 | 0.000 |
*P < 0.05 compared between CRC and CRA. #P < 0.05 compared between CRC and Non-neoplastic controls.
Routine laboratory tests results were showed in Table 2. In comparison with CRA cases and non-neoplastic cases, CRC cases had a lower prevalence of hemoglobin, particularly male CRC cases compared with CRA cases. In comparison with CRA cases and non-neoplastic cases, CRC cases had a lower prevalence of albumin and HDL, but there was no statistical difference for respective male and female cases.
Table 2
routine laboratory tests of colorectal cancer cases, colorectal adenoma cases and non-neoplastic cases.
Characteristic | Colorectal cancer cases | Colorectal adenoma cases | Non-neoplastic cases | F(B) or X2 value | P value |
Hemoglobin(g/dL)*# | 12.62 ± 2.76 | 14.16 ± 1.57 | 13.66 ± 2.24 | 9.783(B) | 0.000 |
Male* | 13.04 ± 2.80 | 14.85 ± 1.41 | 14.14 ± 2.11 | 8.837(B) | 0.000 |
Female | 11.89 ± 2.56 | 13.06 ± 1.11 | 12.82 ± 2.26 | 2.609(B) | 0.081 |
Albumin(g/L)*# | 41.18 ± 4.44 | 42.78 ± 3.18 | 42.44 ± 4.20 | 3.573 | 0.030 |
Male | 41.65 ± 3.93 | 42.86 ± 3.41 | 42.16 ± 4.57 | 1.148 | 0.320 |
Female | 40.36 ± 5.19 | 42.65 ± 2.84 | 42.94 ± 3.46 | 3.688(B) | 0.030 |
Fasting plasma glucose (mmol/L) | 5.27(2.05–12.45) | 5.23(3.64–9.30) | 5.16(3.29–12.19) | 1.525 | 0.467 |
Male | 5.45(2.05–12.45) | 5.31(3.64–9.30) | 5.11(3.29–12.19) | 4.615 | 0.100 |
Female | 5.33 ± 1.08 | 5.35 ± 0.82 | 5.57 ± 1.24 | 0.443 | 0.644 |
TC(mmol/L) | 4.69 ± 1.10 | 4.89 ± 1.18 | 4.67 ± 1.00 | 0.977 | 0.378 |
Male | 4.36 ± 1.00 | 4.76 ± 1.32 | 4.41 ± 0.94 | 1.932 | 0.149 |
Female | 5.28 ± 1.02 | 5.11 ± 0.92 | 5.13 ± 0.94 | 0.282 | 0.755 |
TG(mmol/L) | 1.40(0.48–4.95) | 1.43(0.50–8.61) | 1.30(0.49–6.40) | 4.915 | 0.086 |
Male | 1.34(0.48–4.52) | 1.51(0.71–8.61) | 1.31(0.49–6.40) | 4.337 | 0.114 |
Female | 1.43(0.56–4.95) | 1.29(0.50–7.28) | 1.17(0.62–6.17) | 1.955 | 0.376 |
LDL(mmol/L) | 3.31 ± 0.84 | 3.31 ± 0.74 | 3.24 ± 0.82 | 0.199 | 0.819 |
Male | 13.06 ± 0. 79 | 3.24 ± 0.70 | 3.06 ± 0.8 | 0.909 | 0.405 |
Female | 3.75 ± 0.75 | 3.43 ± 0.80 | 3.57 ± 0. 74 | 1.343 | 0.266 |
HDL(mmol/L)*# | 1.17(0.67–4.37) | 1.24(0.66–4.79) | 1.30(0.46–2.65) | 7.49 | 0.024 |
Male | 1.17 ± 0.35 | 1.21 ± 0.30 | 1.28 ± 0.44 | 1.177(B) | 0.311 |
Female | 1.36 ± 0.67 | 1.52 ± 0.70 | 1.48 ± 0.34 | 0.540 | 0.585 |
*P < 0.05 compared between CRC and CRA. #P < 0.05 compared between CRC and Non-neoplastic controls.
Table 3 showed the anthropometric measurements results. Compared with non-neoplastic patients, the patients with CRC and CRA had greater WC separately (P = 0.036 and P = 0.023), While CRA patients had greater WHR only in female subgroup (P = 0.003). In males, the weight of CRA patients was significantly greater than that of healthy control cases (P = 0.005). When we added the lost weight self-reported to weight measured, we found that both CRC and CRA participators had greater weight than non-neoplastic participators. But those were not found in total and female populations. Compared in three groups, male, female and total patients did not have statistical difference in neck circumference, hip circumference, height, neck-hip ratio, waist-neck ratio, waist-height ratio and BMI.
Table 3
anthropometric measurements of colorectal cancer cases, colorectal adenoma cases and non-neoplastic cases.
Characteristic | Colorectal cancer cases | Colorectal adenoma cases | Non-neoplastic cases | F(B) or X2 value | P value |
Neck circumference (cm) | 37.71 ± 3.57 | 38.94 ± 4.45 | 37.76 ± 3.49 | 2.605 | 0.076 |
Male | 39.43 ± 3.39 | 40.17 ± 3.60 | 38.92 ± 3.33 | 1.671 | 0.192 |
Female | 35.59 ± 2.96 | 37.00 ± 5.01 | 35.72 ± 2.81 | 1.299 | 0.278 |
Waist circumference (cm)#$ | 95.11 ± 11.30 | 95.40 ± 10.68 | 91.70 ± 8.55 | 3.230 | 0.041 |
Male | 96.78 ± 10.53 | 96.20 ± 9.27 | 93.08 ± 8.53 | 2.246 | 0.109 |
Female | 92.17 ± 12.19 | 94.13 ± 12.65 | 89.28 ± 8.15 | 1.414 | 0.249 |
Hip circumference (cm) | 104.91 ± 10.53 | 103.86 ± 8.49 | 101.74 ± 8.56 | 2.451 | 0.088 |
Male | 104.94 ± 9.60 | 104.71 ± 7.41 | 101.37 ± 8.74 | 2.709 | 0.070 |
Female | 104.86 ± 12.18 | 102.52 ± 9.95 | 102.38 ± 8.33 | 0.541 | 0.584 |
Height (cm) | 167.28 ± 8.14 | 167.18 ± 9.13 | 165.45 ± 7.42 | 1.234 | 0.293 |
Male | 170(162–182) | 173(160–184) | 170(158–178) | 10.235 | 0.093 |
Female | 158.72 ± 4.77 | 157.87 ± 4.46 | 157.59 ± 4.92 | 0.459 | 0.633 |
Weight (kg) | 68.30 ± 11.99 | 70.71 ± 12.61 | 66.46 ± 10.35 | 2.651 | 0.073 |
Male$ | 72.41 ± 11.14 | 75.67 ± 11.17 | 69.39 ± 10.54 | 4.110 | 0.018 |
Female | 61.07 ± 9.95 | 62.86 ± 10.74 | 61.31 ± 7.79 | 0.308 | 0.735 |
Neck-hip ratio (NHR) | 0.364 ± 0.031 | 0.376 ± 0.036 | 0.373 ± 0.041 | 2.054 | 0.130 |
Male | 0.377 ± 0.023 | 0.385 ± 0.035 | 0.386 ± 0.041 | 1.092 | 0.338 |
Female | 0.343 ± 0.032 | 0.361 ± 0.034 | 0.350 ± 0.030 | 2..506 | 0.088 |
Waist-neck ratio (WNR) | 2.485(2.06–3.79) | 2.480(1.80–3.10) | 2.390(2.00-3.73) | 4.412 | 0.110 |
Male | 2.46 ± 0.20 | 2.40 ± 0.23 | 2.40 ± 0.26 | 0.961 | 0.385 |
Female | 2.60 ± 0.34 | 2.56 ± 0.27 | 2.51 ± 0.23 | 0.756 | 0.473 |
Waist-hip ratio (WHR) | 0.907 ± 0.065 | 0.917 ± 0.056 | 0.903 ± 0.060 | 1.210 | 0.300 |
Male | 0.923 ± 0.558 | 0.918 ± 0.547 | 0.920 ± 0.064 | 0.072 | 0.930 |
Female$ | 0.880 ± 0.072 | 0.916 ± 0.058 | 0.872 ± 0.036 | 4.860(B) | 0.011 |
Waist-height ratio (WHtR) | 0.569 ± 0.065 | 0.573 ± 0.070 | 0.555 ± 0.052 | 1.795 | 0.168 |
Male | 0.562 ± 0.055 | 0.558 ± 0.057 | 0.548 ± 0.045 | 0.989 | 0.374 |
Female | 0.581 ± 0.080 | 0.597 ± 0.082 | 0.568 ± 0.060 | 1.103 | 0.336 |
Body mass index(BMI) | 24.32 ± 3.29 | 25.25 ± 3.81 | 24.27 ± 3.37 | 2.021 | 0.135 |
Male | 24.38 ± 3.11 | 25.29 ± 3.70 | 24.01 ± 3.41 | 1.849 | 0.161 |
Female | 24.21 ± 3.64 | 25.20 ± 4.04 | 24.72 ± 3.31 | 0.543 | 0.583 |
Weight-adjusted | 69.99 ± 12.26 | 71.02 ± 12.51 | 66.85 ± 10.42 | 2.723 | 0.068 |
Male#$ | 74.20 ± 11.32 | 75.96 ± 11.04 | 69.77 ± 10.75 | 4.206 | 0.017 |
Female | 62.59 ± 10.30 | 63.21 ± 10.70 | 61.72 ± 7.60 | 0.178 | 0.837 |
BMI-adjusted | 24.92 ± 3.43 | 25.37 ± 3.77 | 24.42 ± 3.42 | 1.442 | 0.238 |
Male | 24.99 ± 3.24 | 25.38 ± 3.63 | 24.15 ± 3.52 | 1.664 | 0.193 |
Female | 24.81 ± 3.80 | 25.35 ± 4.05 | 24.89 ± 3.24 | 0.184 | 0.832 |
#P < 0.05 compared between CRC and Non-neoplastic controls. $P < 0.05 compared between CRA and Non-neoplastic controls. Weight-adjusted was equal to weight plus weight loss self-reported. BMI-adjusted was equal to weight-adjusted(kg)/height(m)2.
Proportion of fasting plasma glucose, blood fat and anthropometric measurements was summarized in Supplementary table 1–3 for total, male and female cases. As shown in Supplementary table 1, the proportion of high WNR in CRC and CRA patients was significantly greater than that in non-neoplastic patients. Significant higher proportion of high WHtR was observed in CRA cases compared with non-neoplastic cases. In male subgroup, we found a higher proportion of high hip circumference, WNR and WHtR in CRC patients compared with healthy controls. The proportion of high height, WNR and WHtR in CRA patients was significantly greater than that in non-neoplastic patients (Supplementary table 2). In female subgroup, the proportion of high WHR in both CRC and CRA patients was significantly greater than that in non-neoplastic patients (Supplementary table 3).
We compared the proportion of patients with MetS among three groups according to three different popular definitions for Chinese populations (Table 4). In the total population, the patients with CRC had higher positive rate of MetS according to three definitions than non-neoplastic patients. The CRA patients had higher positive rate of MetS only according to CDS criteria compared with non-neoplastic patients. In males, the proportion of MetS according to three different definitions respectively in CRC and CRA patients was significantly greater than that in control patients. But there were no statistically differences in the female population. Because the most differences were observed by CDS guideline, in addition, its Prevalence was closer to that reported in other literature[39], we calculated the odds ratios and 95%CI in the light of CDS criteria.
Table 4
Proportion of metabolic syndrome defined by three different criteria.
Characteristic | | Colorectal cancer cases | Colorectal adenoma cases | Non-neoplastic cases | X2 value | P value | |
Total | | | | | | | | | |
CDS#$ | Yes | 25 | 31.3 | 24 | 30.0 | 8 | 10.0 | 12.563 | 0.002 |
No | 55 | 68.8 | 56 | 70.0 | 72 | 90.0 |
IDF (Chinese)# | Yes | 47 | 58.8 | 40 | 50.0 | 29 | 36.3 | 8.242 | 0.016 |
No | 33 | 41.3 | 40 | 50.0 | 51 | 63.8 |
NCEPATP III (Asian)# | Yes | 46 | 57.5 | 38 | 47.5 | 27 | 33.8 | 9.151 | 0.010 |
No | 34 | 42.5 | 42 | 52.5 | 53 | 66.3 |
Male | | | | | | | | | |
CDS#$ | Yes | 17 | 33.3 | 15 | 30.6 | 5 | 9.8 | 9.095 | 0.011 |
No | 34 | 66.7 | 34 | 69.4 | 46 | 90.2 |
IDF (Chinese)#$ | Yes | 26 | 51.0 | 24 | 49.0 | 13 | 25.5 | 8.386 | 0.015 |
No | 25 | 49.0 | 25 | 51.0 | 38 | 74.5 |
NCEPATP III (Asian)#$ | Yes | 25 | 49.0 | 23 | 46.9 | 10 | 19.6 | 11.555 | 0.003 |
No | 26 | 51.0 | 26 | 53.1 | 41 | 80.4 |
Female | | | | | | | | | |
CDS | Yes | 8 | 27.6 | 9 | 29.0 | 3 | 10.3 | 3.649 | 0.161 |
No | 21 | 72.4 | 22 | 71.0 | 26 | 89.7 |
IDF (Chinese) | Yes | 21 | 72.4 | 16 | 51.6 | 16 | 55.2 | 3.034 | 0.219 |
No | 8 | 27.6 | 15 | 48.4 | 13 | 44.8 |
NCEPATP III (Asian) | Yes | 21 | 72.4 | 15 | 48.4 | 17 | 58.6 | 3.606 | 0.165 |
No | 8 | 27.6 | 16 | 51.6 | 12 | 41.4 |
#P < 0.05 compared between CRC and Non-neoplastic controls. $P < 0.05 compared between CRA and Non-neoplastic controls.
Table 5–7 shows the univariate and multivariate analysis for association between potential factors and morbidity of CRC and CRA cases. Univariate analysis was adjusted by age and sex for total case, and adjusted by age for male and female cases. Smoking status, drinking history and family cancer history were added to adjusted factors for multivariate Logistic analysis. If the potential risk factors were unrelated to height, height was also added to adjusted factors. We performed Logistic analysis on the factors with statistical differences.
Table 5
Hazard ratios for colorectal cancer compared with colorectal adenoma.
Characteristic | Age and sex-adjusted OR (95% CI) | P value | Multivariable adjusted OR (95% CI) | P value |
Hemoglobin | 0.963(0.946–0.981) | 0.000 | 0.960(0.942–0.979) | 0.000 |
Albumin | 0.902(0.828–0.983) | 0.018 | 0.898(0.822–0.980) | 0.016 |
Weight loss (yes vs. No) | 9.140(3.552–23.516) | 0.000 | 8.227(3.145–21.517) | 0.000 |
HDL | 0.609(0.280–1.324) | 0.211 | 0.646(0.299–1.397) | 0.267 |
Male | Age-adjusted OR (95% CI) | P value | Multivariable adjusted OR (95% CI) | P value |
Weight loss (yes vs. No) | 10.574(2.884–38.770) | 0.000 | 8.405(2.218–31.850) | 0.002 |
Hemoglobin | 0.959(0.937–0.983) | 0.001 | 0.956(0.932–0.980) | 0.000 |
Female | Age-adjusted OR (95% CI) | P value | Multivariable adjusted OR (95% CI) | P value |
Weight loss (yes vs. No) | 7.773(1.904–31.733) | 0.004 | 8.460(1.989–35.984) | 0.004 |
Table 6
Hazard ratios for colorectal cancer compared with colorectal non-neoplastic cases.
Characteristic | Age and sex-adjusted OR (95% CI) | P value | Multivariable adjusted OR (95% CI) | P value |
Hemoglobin | 0.980(0.966–0.995) | 0.009 | 0.979(0.963–0.995) | 0.009 |
Albumin | 0.925(0.852–1.005) | 0.066 | 0.920(0.844–1.003) | 0.059 |
Weight loss (yes vs. No) | 11.072(4.035–30.381) | 0.000 | 10.373(3.665–29.359) | 0.000 |
HDL | 0.537(0.249–1.156) | 0.112 | 0.520(0.239–1.130) | 0.099 |
Diabetes mellitus (yes vs. No) | 3.693(1.278–10.675) | 0.016 | 3.824(1.277–11.450) | 0.017 |
Waist circumference | 1.036(1.002–1.071) | 0.037 | 1.031(0.995–1.067) | 0.091 |
Waist-neck ratio (> 2.45 vs. ≤2.45) | 2.177(1.138–4.164) | 0.019 | 2.426(1.221–4.822) | 0.011 |
MetS (yes vs. No) | 4.005(1.696–9.695) | 0.002 | 3.778(1.539–9.277) | 0.004 |
Male | Age-adjusted OR (95% CI) | P value | Multivariable adjusted OR (95% CI) | P value |
Weight loss (yes vs. No) | 11.189(3.070-40.781) | 0.000 | 10.778(2.779–41.797) | 0.001 |
Diabetes mellitus (yes vs. No) | 4.397(1.147–16.856) | 0.031 | 4.236(1.047–17.137) | 0.043 |
Hip circumference (> 103cm vs. ≤103cm) | 2.838(1.270–6.340) | 0.011 | 2.627(1.108–6.225) | 0.028 |
Waist-neck ratio (> 2.42 vs. ≤2.42) | 2.432(1.088–5.434) | 0.030 | 2.795(1.169–6.680) | 0.021 |
Waist-height ratio (> 0.55 vs. ≤0.55) | 2.651(1.179–5.963) | 0.018 | 3.009(1.260–7.185) | 0.013 |
CDS (yes vs. No) | 4.598(1.544–13.693) | 0.006 | 4.120(1.327–12.795) | 0.014 |
Female | Age-adjusted OR (95% CI) | P value | Multivariable adjusted OR (95% CI) | P value |
Weight loss (yes vs. No) | 10.869(2.163–54.625) | 0.004 | 10.710(2.067–55.504) | 0.005 |
Waist-hip ratio (> 0.890 vs. ≤0.890) | 3.294(1.048–10.348) | 0.041 | 3.354(1.011–11.129) | 0.048 |
Table 7
Hazard ratios for colorectal adenoma compared with colorectal non-neoplastic cases.
Characteristic | Age and sex-adjusted OR (95% CI) | P value | Multivariable adjusted OR (95% CI) | P value |
Waist circumference | 1.042(1.008–1.077) | 0.015 | 1.034(0.999–1.071) | 0.054 |
Waist-neck ratio (> 2.45 vs. ≤2.45) | 2.446(1.275–4.694) | 0.007 | 2.540(1.299–4.968) | 0.006 |
Waist-height ratio (> 0.560 vs. ≤0.560) | 2.354(1.220–4.542) | 0.011 | 2.337(1.205–4.533) | 0.012 |
MetS (yes vs. No) | 3.909(1.629–9.381) | 0.002 | 3.781(1.553–9.208) | 0.003 |
Male | Age-adjusted OR (95% CI) | P value | Multivariable adjusted OR (95% CI) | P value |
Weight | 1.053(1.014–1.094) | 0.008 | 1.035(0.991–1.079) | 0.118 |
Height (> 170cm vs. ≤170cm) | 2.782(1.224–6.324) | 0.015 | 3.134(1.335–7.360) | 0.009 |
Waist-neck ratio (> 2.42 vs. ≤2.42) | 2.802(1.232–6.371) | 0.014 | 2.833(1.193–6.730) | 0.018 |
Waist-height ratio (> 0.550 vs. ≤0.550) | 2.635(1.157–6.005) | 0.021 | 2.780(1.183–6.535) | 0.019 |
MetS (yes vs. No) | 4.076(1.345–12.352) | 0.013 | 3.764(1.204–11.769) | 0.023 |
Female | Age-adjusted OR (95% CI) | P value | Multivariable adjusted OR (95% CI) | P value |
Waist-hip ratio | 1.142(1.032–1.264) | 0.010 | 1.156(1.037–1.289) | 0.009 |
Waist-hip ratio (> 0.890 vs. ≤0.890) | 6.348(1.989–20.265) | 0.002 | 6.253(1.895–20.632) | 0.003 |
We expressed the comparison of CRC and CRA first. In the total population, OR of CRC was reduced by continuous hemoglobin (multivariable-adjusted OR = 0.960, 95%CI: 0.942–0.979) and albumin (multivariable-adjusted OR = 0.898, 95%CI: 0.822–0.980). OR of CRC was enhanced by weight loss self-reported (multivariable-adjusted OR = 8.227, 95%CI: 3.145–21.517). In males, continuous hemoglobin was associated with decreased risk for CRC (multivariable-adjusted OR = 0.956, 95%CI: 0.932–0.980). Weight loss self-reported was correlated with increased risk for CRC (multivariable-adjusted OR = 8.405, 95%CI: 2.218–31.850). In females, OR of CRC was only enhanced by weight loss.
Then we expressed the comparison of CRC and colorectal non-neoplastic cases. Among the 240 patients, OR of CRC was reduced by continuous hemoglobin (multivariable-adjusted OR = 0.979, 95%CI: 0.963–0.995). OR of CRC was enhanced by diabetes (multivariable-adjusted OR = 8.227, 95%CI: 3.145–21.517), MetS by CDS (multivariable-adjusted OR = 3.778, 95%CI: 1.539–9.277), waist-hip ratio in the high half (multivariable-adjusted OR = 3.778, 95%CI: 1.539–9.277) and weight loss self-reported (multivariable-adjusted OR = 10.373, 95%CI: 3.665–29.359). In male patient subgroup, OR of CRC was also enhanced by diabetes, MetS by CDS and weight loss self-reported. A significant increased risk for CRC was observed between the high and low halves of hip circumference (multivariable-adjusted OR = 2.627, 95%CI: 1.108–6.225), WNR (OR = 2.795, 95%CI: 1.169–6.680) and WHtR (OR = 3.009, 95%CI: 1.260–7.185). In female patient subgroup, OR of CRC was enhanced by WHR in the high half (multivariable-adjusted OR = 3.354, 95%CI: 1.011–11.129) and weight loss self-reported.
Because of the close relationship of CRC and CRA, the comparison of CRA and colorectal non-neoplastic cases was also important. MetS by CDS, WNR and WHtR from the high half were associated with increased risk for CRA cases compared with colorectal non-neoplastic cases. Male patients with MetS by CDS, WNR, WHtR and height from the high half had a greater risk than their counterparts from the low half. Both continuous and grouped WHR was correlated with increased risk for CRA in females.